当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
HYQVIA, Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase
药品名称
HYQVIA, Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase
承诺描述
Baxter commits to conducting an evaluation of long-term safety study of HYQVIA in 250 patients with PID including up to 50 patients developing antibodies. The duration of the study is 6 years and subjects who become antibody positive will be eligible for further long term safety evaluation and antibody characterization.